Evidence map›Paper›PMID 28945791›Full record

ArticlePloS one2017

Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.

Ai Zhao, Fahai Chen, Chunhong Ning, Haiming Wu, Huanfang Song, Yanqing Wu, Rong Chen, Kaihua Zhou, Xiaoling Xu, Yinxiang Lu and 1 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ai ZhaoZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Fahai ChenZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chunhong NingZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Haiming WuZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Huanfang SongZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yanqing WuZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Rong ChenHospital 212 of the Nuclear Industry, Wuwei, Gansu, China.
Kaihua ZhouZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaoling XuZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yinxiang LuZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jimin GaoZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, School of Laboratory Medicine& Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.ORCID http://orcid.org/0000-0003-3089-0342
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we developed a rapid strategy to screen a serum-free medium for culturing the anchorage-dependent PC-3 prostate cancer cells, which was going to be prepared in large scale to generate GM-CSF/TNFα-surface-modified whole cell prostate cancer vaccine. Automated real-time cellular analysis as a rapid and non-invasive technology was used to monitor the growth of PC-3 cells in 16-well plates. At the same time, Plackett-Burman design was employed to identify the most influential formulation by integrating relevant information statistically. The effects of the 16 selected factors were evaluated during exponential cell growth and three medium constituents (EGF, FGF and linoleic acid) were identified to have significant effects on the cell growth. Subsequently, the response surface methodology with central composite design was applied to determine the interactions among the three factors so that these factors were optimized to improve cell growth. Finally, the prediction of the best combination was made under the maximal response to optimize cell growth by Design-Expert software 7.0. A total of 20 experiments were conducted to construct a quadratic model and a second-order polynomial equation. With the optimized combination validated by the stability test of serial passaging PC-3 cells, the serum-free medium had similar cell density and cell viability to the original serum medium. In summary, this high-throughput scheme minimized the screening time and may thus provide a new platform to efficiently develop the serum-free media for adherent cells.

Indexed as

Cancer VaccinesCell AdhesionCell Culture TechniquesCell Line, TumorCell ProliferationCell SurvivalComputer SystemsCulture Media, Serum-FreeEpidermal Growth FactorFibroblast Growth FactorsHigh-Throughput Screening AssaysHumansLinoleic AcidMaleProstatic NeoplasmsSoftwareCancer VaccinesCulture Media, Serum-FreeEpidermal Growth FactorFibroblast Growth FactorsLinoleic Acid

Identifiers

PMID28945791
PMCPMC5612757
OpenAlexW2759758144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.